Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SERCA 2a gene therapy - Theragene Pharmaceuticals

Next Previous
Drug Profile

SERCA 2a gene therapy - Theragene Pharmaceuticals

Alternative Names: AAV1/SERCA2a; AAV1/SSERCA2a; MYDICAR; rAAV1-SERCA2a; SERCA2a gene therapy; SRD-001; SRD-002; SRD-003

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celladon; Targeted Genetics
  • Developer Eiger BioPharmaceuticals, Inc.; Sardocor; Theragene Pharmaceuticals
  • Class Gene therapies; Heart failure therapies
  • Mechanism of Action Adenosine triphosphatase stimulants; Gene transference; Sarcoplasmic reticulum calcium-transporting ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cardiomyopathies; Heart failure
  • No development reported Pulmonary arterial hypertension; Renal failure
  • Discontinued Urinary incontinence

Most Recent Events

  • 01 Apr 2025 Adverse events and efficacy data from a phase I/II trial in Heart failure released by Medera
  • 11 Mar 2025 Medera completes enrolment in the phase I/II MUSIC-HFrEF trial for Heart failure in the USA (Intracoronary) (NCT04703842)
  • 24 Oct 2024 Adverse events data from a phase I/II trial in Heart failure released by Medera

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top